N-terminus and C-terminus

what is the N-terminus and C-terminus? The N-terminus is the beginning of a peptide chain, with its free amino group; the C-terminus is the other end, with its free carboxyl group. Standard peptide sequences run from N to C, left to right. Chemists can modify either end to change stability, charge, or activity.

Which end is the N-terminus, and which is the C-terminus?

The N-terminus is the amino end and the C-terminus is the carboxyl end of a linear peptide. A compact N-terminus meaning is “the start of the chain.” The matching C-terminus definition is “the chain’s carboxyl end.” The letters come from nitrogen in the amino group and carbon in the carboxyl group.

Each amino acid begins with both an amino group and a carboxyl group. Linking amino acids into a chain uses those groups to make peptide bonds. Most are therefore tied up inside the backbone, but one amino group remains available at one end and one carboxyl group remains available at the other. Those are the two termini; termini is simply the plural of terminus.

Around normal body pH, the unmodified N-terminal amino group is often positively charged and the unmodified C-terminal carboxyl group is often negatively charged. That charge can affect how a peptide folds, dissolves, meets a receptor, and gets recognized by enzymes. The ends are not decorative punctuation.

How do you read a peptide sequence from N to C?

Every standard linear peptide sequence on this site is written with the N-terminus first and the C-terminus last, normally left to right. The first letter is residue 1 unless the page says the sequence is a numbered fragment of a larger parent molecule. The amino acid sequence glossary explains the one-letter and three-letter codes behind that line of letters.

For a made-up sequence A-G-S, alanine is N-terminal, serine is C-terminal, and glycine sits between them. Reversing it to S-G-A does not give a second spelling of the same peptide. It describes a different chain. A quick memory aid for peptide ends: amino means N; carboxyl means C.

The NCBI Bookshelf biochemistry reference confirms both points: the free amino group marks the N-terminal end, the open carboxyl group marks the C-terminal end, and sequences are read N to C. That convention is the small piece of chemistry that unblocks nearly every sequence page.

What do “N-terminal fragment” and “C-terminal fragment” mean?

An N-terminal fragment comes from the beginning of a larger parent chain; a C-terminal fragment comes from its end. The label describes where the piece sat in the parent molecule. Once separated or synthesized as its own linear peptide, the fragment also has an N-terminus and C-terminus of its own. Parent position and standalone peptide end are related, but they are not the same question.

HGH Fragment 176–191 makes this concrete. The site calls it a C-terminal fragment because residues 176–191 come from the tail of human growth hormone. Read as a standalone sequence, residue 176 becomes that fragment’s N-terminal residue and residue 191 remains its C-terminal residue.

The thymosin beta-4 profile gives the less obvious case. Thymosin beta-4 is 43 amino acids long, while the fragment discussed there centers on residues 17–23. That piece came from the middle of the parent, so neither edge was an original thymosin beta-4 terminus. Cutting out the piece creates a new amino end at residue 17 and a new carboxyl end at residue 23. “Fragment” does not automatically mean “terminal fragment.”

Why do chemists acetylate or amidate peptide ends?

Chemists often use N-terminal acetylation or C-terminal amidation to cap exposed peptide ends. Acetylation changes the N-terminal amino group; amidation converts the C-terminal carboxyl group to a carboxamide. These edits can reduce recognition by exopeptidases, enzymes that remove residues from an exposed end, and they also change the terminal charge.

The practical image is enzymes chewing from either end of a loose string. A cap may make the first bite harder. A 2021 review of protease-resistant peptide engineering identifies N-terminal acetylation and C-terminal amidation as the most common terminal protections against aminopeptidases and carboxypeptidases.

“May” matters. End-capping does not make a peptide enzyme-proof. Endoproteases can still cut bonds inside the sequence, and a terminal edit can change receptor affinity or the shape needed for activity. The same review warns that stability-focused modifications can lower target affinity and are not universally transferable between peptides. A label such as Ac- at the left or -NH2 at the right therefore reports real chemistry, not automatic proof of a longer human half-life.

What evidence tier applies to terminal modifications?

For readers asking what is the N-terminus and C-terminus, the definitions and N-to-C sequence direction are settled chemistry, not clinical outcome claims. The broader claim that terminal protection can resist enzyme cleavage is supported by biochemical and peptide-engineering evidence. Whether a particular acetylated or amidated peptide lasts longer, binds better, or works in people must be tested for that exact molecule.

That separation is the useful evidence check. Mechanism: capping an exposed end can block some exopeptidase recognition. Molecule-level evidence: a stability assay can compare capped and uncapped versions. Human evidence: pharmacokinetic or clinical testing must show what happens in people. Skipping from the first rung to the third is how a small notation mark turns into a large marketing claim.

When a sequence begins with Ac-, read it as an acetylated N-terminus. When it ends with -NH2, read it as an amidated C-terminus. When neither appears, do not assume the ends are modified unless the source states that they are. Sequence, terminal chemistry, and evidence belong on the same label; none should be guessed from the other two.